Companiesandmarkets.com

Parkinson's disease market controlled by dopamine agonists with a 30% share

Press Release   •   Aug 22, 2013 12:28 BST

The Parkinson's disease market has been forecast to increase at a compound annual growth rate (CAGR) of 1.67% through 2016, driven by the rise in the aging population, and the transition toward using drugs that have new mechanisms of action.

The uptake of key current brands and the launch of three new therapies will help sustain the Parkinson's disease (PD) market throughout the 2012-2022 period, despite growing competition from generics.

Dopamine agonists will maintain the largest class-level market share through 2022 at approximately 30%. For the drug-class leaders, pramipexole and ropinirole, a growing reliance on convenient once-daily formulations is expected to render the original, three-times-daily formulations nearly obsolete by the second half of 2012-2022.

Parkinson's disease is a degenerative disorder of the central nervous system. The motor symptoms of Parkinson's disease result from the death of dopamine-generating cells in the substantia nigra, a region of the midbrain; the cause of this cell death is unknown.

Early in the course of the disease, the most obvious symptoms are movement-related; these include shaking, rigidity, slowness of movement and difficulty with walking and gait. Later, thinking and behavioural problems may arise, with dementia commonly occurring in the advanced stages of the disease, whereas depression is the most common psychiatric symptom.

Vaccine development is undergoing significant advancements in the market; with special focus being given to neurodegenerative diseases such as Parkinson's disease.

There isn't a single drug available that can modify the course of the disease. AFFiRiS AG, an Australian pharmaceutical company, is involved in the first-ever Phase I clinical development trial for Parkinson's disease (PD01A). The vaccine targets the protein alpha-Synuclein, which is responsible for the onset of the disease. PD01A is expected to encourage disease modifying effects and not symptomatic relief.

Key players currently dominating the Parkinson's disease market include GlaxoSmithKline plc, Novartis AG, Orion Corp., and Teva Pharmaceuticals Industries Ltd.

For more information on the Parkinson's disease market, see the latest research: Parkinson's Disease Market

Follow us on Twitter @CandMResearch

Companiesandmarkets.com issues news updates and report summaries covering all major industries and sectors. The service provides additional client monitoring and timely alerts to breaking industry and sector news leading the day's business headlines. News articles, written by our staff, contain additional analyst insight, providing value added insight for our readers. News updates and real-time alerts on newly-released market reports are also available from our Facebook page, Twitter feed @CandMResearch and RSS links. We also welcome inquiries from business journalists and the news media.